30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Anna Protopapas

Track

Insider profile

Currently holds positions in Dicerna Pharmaceuticals Inc and Mersana Therapeutics Inc

Performance

Overall performance
2.6
Performance over holding periods
2.6
30 days 90 days 120 days
Average return 1% 8.2% 15.1%
Success rate 79% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Dicerna Pharmaceuticals Inc Jan. 23, 2019 -
President, Chief Executive Officer, Director Mersana Therapeutics Inc March 1, 2015 -
Independent Director Bioverativ Inc Feb. 1, 2017 - March 8, 2018
Independent Director ARIAD Pharmaceuticals Inc April 28, 2015 - Feb. 16, 2017
Anna Protopapas's trades of Mersana Therapeutics Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-17 2025-01-16
PrS Proposed sale
48,202
374.25
US$3,833,692 		48,202 374.25 US$3,833,692
2025-01-17 2025-01-16
PlS Planned sale
58,287 +48.3%
487.71
US$4,724,800 		58,287 +48.3% 487.71 US$4,724,800
2025-01-16 2025-01-15
PrS Proposed sale
34,724
463.61
US$3,751,916 		34,724 463.61 US$3,751,916
2025-01-16 2025-01-15
PlS Planned sale
6,191 -3.8%
0.63
US$3,900 		6,191 -3.8% 0.63 US$3,900
2025-01-15 2025-01-14
PrS Proposed sale
11,534
0.63
US$7,266 		11,534 0.63 US$7,266
2025-01-15 2025-01-14
PlS Planned sale
11,534 -7.4%
0.66
US$7,612 		11,534 -7.4% 0.66 US$7,612
2024-01-17 2024-01-16
PlS Planned sale
29,399 -19.0%
2.71
US$79,671 		29,399 -19.0% 2.71 US$79,671
2024-01-16 2024-01-16
PrS Proposed sale
29,399
3.02
US$88,785 		29,399 3.02 US$88,785
2023-12-20 2023-12-18
US Nuvalent Inc (NUVL)
S Sale
5,000 -100.0%
75.67
US$378,350 		5,000 -100.0% 75.67 US$378,350
2023-12-18 2023-12-18
US Nuvalent Inc (NUVL)
PrS Proposed sale
10,000
74.43
US$744,300 		10,000 74.43 US$744,300
2023-01-18 2023-01-17
S Sale
17,346 -26.3%
5.74
US$99,566 		17,346 -26.3% 5.74 US$99,566